KELLEY DRYE & WARREN LLP for PLASMA PROTEIN THERAPEUTICS ASSOCIATION
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
House and Senate Labor HHS Appropriations; issues relating to FDA regulations, drug safety, follow-on biologics
Foreign entity interest: Grifols, S.A., and Octapharma AG, as members of Plasma Protein Therapeutics Association Global, have an interest in FDA regulations, drug safety and biologics.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK JOSEPH ANDERSON | — |
| MAGGIE CLARKE CROSSWY | — |
| WILLIAM KLINEFELTER | — |
| DANA SCHNEEBERGER WOOD | — |
Medicare/Medicaid MMM
General issues regarding Medicare and Medicaid; Hr 2914, S 2990, regarding intravenous immunoglobulin (IVIG); HR 6331 and S 3101, regarding Medicare improvements for patients and providers; S 558, HR 1424, Mental Health Parity, as it relates to Medicaid rebate
Foreign entity interest: Grifols, S.A., and Octapharma AG, as members of Plasma Protein Therapeutics Association Global, have an interest in U.S. Medicare and Medicaid programs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK JOSEPH ANDERSON | — |
| MAGGIE CLARKE CROSSWY | — |
| WILLIAM KLINEFELTER | — |
| DANA SCHNEEBERGER WOOD | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| OCTAPHARMA AG | Switzerland | Switzerland | — | — |
| GRIFOLS, S.A. | Spain | Spain | — | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.